Old drug, new hope? pentoxifylline trial targets jaundice
NCT ID NCT06944704
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This completed Phase 2 trial tested whether the drug pentoxifylline can help people with jaundice caused by liver or bile duct problems. 45 adults took 400 mg of pentoxifylline twice daily for 3 months, alongside standard care. Researchers measured changes in antioxidant levels, inflammation, and liver function to see if the drug improves bilirubin and liver health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pentoxifylline
- What this could lead to
- If it works, this could point toward a new way to reduce jaundice and improve liver function in people with liver or bile duct problems.
- What could go wrong
- This is a small, early-phase trial with only 45 people, so results may not apply to everyone. Pentoxifylline can cause side effects like nausea or bleeding risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOBILIARY DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Pharmacy, Tanta University
Tanta, 31111, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.